The assessment of absorption, distribution, metabolism, and excretion (ADME) properties of compounds is a key component in supporting stroke drug discovery and development. In vitro testing is well suited to test potential stroke drugs at an early stage under well-controlled testing conditions. In vitro testing requires fewer resources than in vivo and is often much faster. In vitro ADME helps drug developers gain insight into metabolism and potential drug-drug interactions, as well as the suitability of stroke drug candidates for further research by studying the absorption, distribution, metabolism, and excretion characteristics of drug candidates.
Ace Therapeutics specializes in the field of stroke and provides comprehensive in vitro ADME services to efficiently assess the absorption, distribution, metabolism, and excretion of stroke drugs to help advance promising stroke drug candidates through preclinical development.
We offer a wide range of in vitro ADME assays for stroke small molecules, biologics, and more. These assay formats can be adapted to different stages of the stroke drug discovery and development process, providing a flexible approach to ADME screening. Choosing from a range of assays allows us to select the assay that best meets your throughput, data resolution and quality needs, and achieves your project-specific goals.
Physicochemical Screening | Kinetic and thermodynamic solubility testing of stroke drugs |
Absorption | Permeability Assays We offer a variety of assays to study the permeability of stroke drugs, such as Caco-2, MDCK, MDCK-MDRI, and MDCK-BCRP. We offer LC-MS/MS bioassays to measure stroke drug levels in the apical and basolateral cell monolayer. |
Distribution | Protein Binding Assays We offer a variety of in vitro binding assays including plasma protein binding (PPB), brain tissue binding, and plasma partitioning (BPP). Protocols can be flexibly adapted to specific customer requirements. |
Metabolism | Metabolic Stability
|
Drug-Drug Interaction Assays
|
|
Excretion | We can use UPLC-MS to analyze bile, stool, or urine samples as well as tissues to quantify stroke drug and metabolite levels. |
Our in vitro ADME testing can help clients gain insight into the DMPK properties of their stroke drug candidates. Obtaining this information early in the discovery and development process has many advantages, including:
Ace Therapeutics can help customize a comprehensive strategy by providing ADME analysis packages for stroke drug candidates. Our laboratory testing department has the expertise to ensure that your drug's in vitro ADME testing follows a best-in-class process, while providing you with the data-driven support you need to advance your compound candidate to the next milestone. If you are interested in our services, please do not hesitate to contact us!
We are committed to accelerating progress in stroke research and drug development.